0
nAbbing SARS-CoV-2 variants
New SARS-CoV-2 variants mean new neutralizing antibodies to deal with them. With the COVID-19 pandemic on its third wave in some…
Browsing: Basic > Immunology
0
What effect will SARS-CoV-2 variants have on vaccine efficacy?
The ‘inevitable’ domination of novel SARS-CoV-2 variants from Brazil, South Africa and the UK could result in less effective COVID-19…
0
Natural immunity to COVID-19: how long and how strong?
Two recent papers from Public Health England (PHE; London, UK) and Rockefeller University (NY, USA) have shed new light on the duration and quality of protection provided…
0
What are the advantages of the Oxford—AstraZeneca COVID-19 vaccine?
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly…
0
What is the extent of SARS-CoV-2 immunity post-exposure?
The question of COVID-19 immunity is on everyone’s lips. It is crucial to understand how immunity develops post-exposure to the virus…
0
Cytokine storm could sabotage long-term immunity against SARS-CoV-2
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
0
Nanobodies engineered from llama antibodies show immunity against SARS-CoV-2
A research team from The Rosalind Franklin Institute, Diamond Light Source, The University of Oxford and Public Health England have engineered nanobodies from llama antibodies that show protective immune effects against SARS-CoV-2.
0
COVID-19 research round-up: June
This month’s top COVID-19 research articles include several studies citing the benefits of facemasks, as well as research investigating adaptive immunity to SARS-CoV-2 and a genome-wide study exploring COVID-19 severity.
0
Researchers identify inflammatory molecules as potential targets for COVID-19
Researchers have accurately profiled the immune response to COVID-19 in critically ill patients, allowing them to identify six inflammatory molecules as potential targets for COVID-19 treatment.
0
Adaptive study design and the potential of convalescent plasma therapy for COVID-19 – an interview with José Javier García
In this interview we speak to José Javier García from Pivotal about his company´s involvement in a large-scale clinical trial testing the safety and efficacy of hyperimmune convalescent plasma treatment in COVID-19 patients.